Literature DB >> 11885931

Early gene expression of vaccinia virus strains replicating (Praha) and non-replicating (modified vaccinia virus strain Ankara, MVA) in mammalian cells.

S Nemecková1, P Hainz, P Otáhal, P Gabriel, V Sroller, L Kutinová.   

Abstract

Modified vaccinia virus Ankara strain (MVA) is a safe highly attenuated non-pathogenic virus suitable as a vector for developing various vaccines. Study of expression of a reporter beta-galactosidase gene under the control of an early vaccinia virus (VV) promoter in MVA and non-modified vaccinia virus Praha strain showed that early transcription in MVA is elevated in comparison with non modified VV. This property was demonstrated in various cell cultures including CV1 cells, human lung diploid cells, chicken primary fibroblasts but not in bone marrow-derived mouse dendritic cells. There the relationship between the elevated early transcription and the permisivity of cells for MVA was not observed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11885931

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  4 in total

1.  Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses.

Authors:  Edwin R Manuel; Zhongde Wang; Zhongqi Li; Corinna La Rosa; Wendi Zhou; Don J Diamond
Journal:  Virology       Date:  2010-05-14       Impact factor: 3.616

2.  Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses.

Authors:  Michael Wolferstätter; Marc Schweneker; Michaela Späth; Susanne Lukassen; Marieken Klingenberg; Kay Brinkmann; Ursula Wielert; Henning Lauterbach; Hubertus Hochrein; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2014-10-08       Impact factor: 5.103

3.  In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate.

Authors:  Malachy Ifeanyi Okeke; Øivind Nilssen; Ugo Moens; Morten Tryland; Terje Traavik
Journal:  Virol J       Date:  2009-05-12       Impact factor: 4.099

4.  Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.

Authors:  Jarmila Knitlova; Vera Hajkova; Ludek Voska; Jana Elsterova; Barbora Obrova; Zora Melkova
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.